M. Kraus & Co Trims Stake in Abbott Laboratories $ABT

M. Kraus & Co trimmed its stake in Abbott Laboratories (NYSE:ABT) by 1.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,190 shares of the healthcare product maker’s stock after selling 1,204 shares during the period. Abbott Laboratories accounts for approximately 3.1% of M. Kraus & Co’s holdings, making the stock its 11th largest position. M. Kraus & Co’s holdings in Abbott Laboratories were worth $10,499,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ABT. Hughes Financial Services LLC purchased a new stake in Abbott Laboratories in the 1st quarter worth $27,000. Abound Financial LLC purchased a new stake in Abbott Laboratories in the 1st quarter worth $28,000. Elequin Capital LP purchased a new stake in Abbott Laboratories in the 1st quarter worth $30,000. JCIC Asset Management Inc. purchased a new stake in Abbott Laboratories in the 1st quarter worth $32,000. Finally, Vision Financial Markets LLC purchased a new stake in Abbott Laboratories in the 1st quarter worth $33,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ABT has been the subject of a number of analyst reports. Royal Bank Of Canada increased their price target on Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 15th. Raymond James Financial dropped their price objective on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a report on Friday, July 18th. Mizuho increased their price objective on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a report on Wednesday, July 16th. Evercore ISI increased their price objective on shares of Abbott Laboratories from $140.00 to $144.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $146.24.

Abbott Laboratories Stock Down 0.8%

Shares of NYSE:ABT opened at $133.24 on Friday. The company has a market cap of $231.90 billion, a price-to-earnings ratio of 16.70, a PEG ratio of 2.55 and a beta of 0.69. The company has a 50-day moving average price of $132.44 and a 200 day moving average price of $131.52. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. Abbott Laboratories’s revenue was up 7.4% compared to the same quarter last year. During the same period last year, the company posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.46% of the stock is currently owned by insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.